“ALL-IN-ONE VIRUSES” How PsiOxus is building a gene therapy cancer platform on its oncolytic virus – BIOCENTURY

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells wherever they reside.